1.
Targeting Circadian Rhythm Disruption in Glaucoma: PTGDS Mediates Trabecular Meshwork Fibrosis and Is Therapeutically Targeted by Aprepitant.
Yuan Hongzhi, Che Yutong, Zhang Yuqing, Cai Ziyi, Ping Yu-Tzu, Wang Xiaoran et al.
Transl Vis Sci TechnolMay 20260 citationsBasic Science
This study found the circadian-related gene PTGDS drives trabecular meshwork fibrosis in glaucoma. Aprepitant, an existing drug, effectively targeted PTGDS in vitro, offering a promising repurposed therapy for ocular hypertension.